Balanced news tone
News Sentiment
LSTA sentiment intelligence
Lisata Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-1.8% over one week, -8.1% over four weeks, trend inactive, and near fair-value range.
Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:21
- Source
- Stock Titan
Price to sales forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 16:20
- Source
- TradingView
Lisata Therapeutics (LSTA) Q3 2025 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline - EPS Growth Rate
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 17:48
- Source
- dars.gov.et
Lisata Therapeutics (LSTA) amends 14D-9, restates $4.00 cash offer plus CVR
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 07:00
- Source
- Stock Titan
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Market source
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- GlobeNewswire
Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Lisata Therapeutics (LSTA) Eases Amid Modest Pullback — Key Support Levels in Focus - Volatility Surface
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- DonanımHaber
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jun 2026 07:00
- Source
- Investing.com
Lisata Therapeutics (LSTA) Slightly Lower: Assessing Support Levels and Potential Catalysts - Sign of Weakness
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- DonanımHaber
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- Stock Titan
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 17 Mar 2026 03:48
- Source
- Kavout | AI
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Mar 2026 08:00
- Source
- GlobeNewswire
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- Stocktwits
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- citybiz
Lisata Therapeutics Enters Into Term Sheet to be Acquired
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- GlobeNewswire
Lisata Therapeutics (LSTA) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2025 16:45
- Source
- Stock Titan